American Bio Medica has a Cash Ratio of 0.06. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for American Bio Medica's Cash Ratio or its related term are showing as below:
ABMC's Cash Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.92 * Ranked among companies with meaningful Cash Ratio only.
American Bio Medica Cash Ratio Historical Data
The historical data trend for American Bio Medica's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of American Bio Medica's Cash Ratio
For the Diagnostics & Research subindustry, American Bio Medica's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
American Bio Medica's Cash Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Cash Ratio distribution charts can be found below:
* The bar in red indicates where American Bio Medica's Cash Ratio falls into.
American Bio Medica Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
American Bio Medica's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
American Bio Medica (OTCPK:ABMC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
American Bio Medica Cash Ratio Related Terms
Thank you for viewing the detailed overview of American Bio Medica's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
American Bio Medica (American Bio Medica) Business Description
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABMC has been successfully added to your 